The TFIID complex is a new autoantibody target in systemic sclerosis
(2026) Annals of the Rheumatic Diseases — Vol. 85, n° 2, p. 393-395 (2026)
Files
2026_Vulsteke_Ann_Rheum_Dis.pdf
Accepted author manuscript
Open Access - Adobe PDF
- 1.34 MB
Details
- Authors
Bossuyt, Xavier 
- Abstract
- (en) Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups. [...]
- Affiliations
Citations
Vulsteke, J.-B., Michiels, B., Smith, V., Piette, Y., Vanthuyne, M., Lacout, C., Brochard, A., Tikly, M., De Leeuw, J., Dillaerts, D., Dehaemers, T., De Haes, P., Lenaerts, J. L., Blockmans, D., McHugh, N., Tansley, S., Vinatier, E., Houssiau, F., Bonroy, C., et al. (2026). The TFIID complex is a new autoantibody target in systemic sclerosis. Annals of the Rheumatic Diseases, 85(2), 393-395. https://doi.org/10.1016/j.ard.2025.05.008 (Original work published 2026)